Providing progressive cancer treatment and compassionate care.

Cancer News – 2018

  • Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

    Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). About Head and Neck Cancer Head and neck cancers include a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and … Continue reading "Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN" […]

  • FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer

    On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. Xtandi was previously approved for the treatment of patients with metastatic CRPC. About Prostate Cancer Prostate cancer is … Continue reading "FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer" […]

  • Cyramza Improves Survival in Poor-Prognosis Liver Cancer

    Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer (WCGC) demonstrating that Cyramza (ramucirumab) significantly improves survival in a subset of patients with hepatocellular carcinoma (HCC) who have high levels of the plasma protein α-fetoprotein (AFP), which is associated … Continue reading "Cyramza Improves Survival in Poor-Prognosis Liver Cancer" […]

  • Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

    Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis according to the results of a study published in the Journal of … Continue reading "Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer" […]

  • Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients

    Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American … Continue reading "Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients" […]

  • Engineering the Common Cold Virus Appears to be Promising Treatment Approach for Some Brain Tumors

    A “smart bomb” oncolytic adenovirus appears to induce dramatic responses with long-term survival in recurrent high-grade gliomas, according to the early results of a study published in The Journal of Clinical Oncology. Glioblastoma is the most common and aggressive form of primary brain cancer in adults. With standard therapy — surgery followed by chemoradiation and … Continue reading "Engineering the Common Cold Virus Appears to be Promising Treatment Approach for Some Brain Tumors" […]

  • Xalkori® Receives FDA Breakthrough Therapy Designation for Anaplastic Large Cell Lymphoma

    The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori® (crizotinib) for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine if it is intended … Continue reading "Xalkori® Receives FDA Breakthrough Therapy Designation for Anaplastic Large Cell Lymphoma" […]

  • FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion,

    The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval was based on a multicenter, open-label clinical trial of venclexta with rituximab (VEN+R) versus bendamustine with rituximab (B+R) … Continue reading "FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion," […]

  • Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer

    The results of a recent study published in The Journal of Clinical Oncology suggest the first new therapeutic option for Small Cell Lung Cancer (SCLC) in many years.  The study evaluated the addition of a novel precision cancer medicine called a PARP inhibitor to standard chemotherapy improved overall response rates and delayed cancer progression in patients … Continue reading "Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer" […]

  • Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer

    An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda (pembrolizumab) plus traditional chemotherapy compared with those who received placebo plus chemotherapy. About Lung Cancer Lung cancer remains the leading cause … Continue reading "Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer" […]